Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity

Domaine:

healthcare
Créateur:
JyoSupRanNit
Éditeur:
ope
Hôte:
Abstract Evolving diversity in globally circulating HIV-1 subtypes presents formidable challenge in defining and developing neutralizing antibodies for prevention and treatment. HIV-1 subtype C is responsible for majority of global HIV-1 infections. Broadly neutralizing antibodies (bnAbs) capable of neutralizing distinct HIV-1 subtypes by targeting conserved vulnerable epitopes on viral envelope protein (Env) are being considered as promising antiviral agents for prevention and treatment. In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific global HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities. A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database ( www.hiv.lanl.gov ). The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS). Responses of these sequences to bnAbs were predicted with a machine learning algorithm ‘bNAb-ReP’ and compared with those reported in the CATNAP database. Phylogenetically, sequences from Asian countries including India clustered together however differed significantly when compared with pan African subtype C sequences. Variable loop lengths within Indian and African clusters were distinct from each other, specifically V1, V2 and V4 loops. Furthermore, V1V2 and V2 alone sequences were also found to vary significantly in their charges. Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles. Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C. Our findings highlight that the distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.

Visit

doi.org

Licenses

http://creativecommons.org/licenses/by-nc-nd/4.0/

Similaires

HIV-1 DNA sequence diversity and evolution during acute subtype C infectionNeutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progressionHIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysisBroadly neutralizing antibody VRC34-combo.1 in complex with HIV fusion peptide (residue 512-519)Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolatesA Potent, Neutralizing Human Monoclonal Antibody against a Unique Epitope Overlapping the CD4-Binding Site of HIV-1 gp120 That Is Broadly Conserved across North American and African Virus Isolates

HIV-1 DNA sequence diversity and evolution during acute subtype C infection

Abstract Little is known about the genotypic make-up of HIV-1 DNA genomes during the earliest stage

Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis

Abstract Background Entry inhibitors, such as Maraviroc, hold promise as components of HIV trea

Broadly neutralizing antibody VRC34-combo.1 in complex with HIV fusion peptide (residue 512-519)

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates

Abstract Novel therapeutic and preventive strategies are needed

A Potent, Neutralizing Human Monoclonal Antibody against a Unique Epitope Overlapping the CD4-Binding Site of HIV-1 gp120 That Is Broadly Conserved across North American and African Virus Isolates

A human monoclonal antibody (HuMAb), 5145A, against HIV-1 gp120 was isolated from an asymptomatic, s